CD19 CAR T Efficacy Is Consistent Across Race in B-Cell LymphomasByAndrea Eleazar, MHSMarch 31st 2026
Axi-Cel’s QOL Gains in R/R LBCL Extend to Transplant-Ineligible Patients ByAndrea Eleazar, MHSMarch 26th 2026
Venetoclax/Ibrutinib Safe, Induces Durable Response in Marginal Zone LymphomaByAndrea Eleazar, MHSMarch 25th 2026